WO2007148787A1 - 2-(3-シアノ-4-イソブチルオキシフェニル)-4-メチル-5-チアゾールカルボン酸の結晶多形体の製造方法 - Google Patents
2-(3-シアノ-4-イソブチルオキシフェニル)-4-メチル-5-チアゾールカルボン酸の結晶多形体の製造方法 Download PDFInfo
- Publication number
- WO2007148787A1 WO2007148787A1 PCT/JP2007/062593 JP2007062593W WO2007148787A1 WO 2007148787 A1 WO2007148787 A1 WO 2007148787A1 JP 2007062593 W JP2007062593 W JP 2007062593W WO 2007148787 A1 WO2007148787 A1 WO 2007148787A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- methanol
- crystal
- methyl
- isobutyloxyphenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Definitions
- the present invention relates to a method for producing a crystal A of 2- (3 cyano 4-isobutyloxyphenyl) 4-methyl 5 thiazolecarboxylic acid.
- This compound has an action of regulating biosynthesis of uric acid in a living body, and can be used as a therapeutic agent for hyperuricemia.
- Patent Document 1 describes A crystal, B crystal, C crystal, D crystal, and G crystal. The presence of five crystalline polymorphs and an amorphous material, and methods for their production are disclosed.
- the production method of the crystalline polymorph shown here is 2- (3-cyan-4-isobutyloxyphenyl) -4-methyl-5-thiazole carboxylic acid with the specified methanol Z water mixed solvent The mixture is heated and stirred to dissolve it, and then added to water and cooled to set the predetermined methanol Z water composition and temperature, and then the crystals are collected by filtration and dried to obtain each crystal polymorph. To manufacture.
- Patent Document 2 discloses a solution dissolved in a methanol or methanol Z water mixed solvent.
- (3 cyano 4 isobutyloxyphenyl) 4 methyl 5-thiazolecarboxylic acid is a method for producing a crystalline polymorph by adding water, characterized by changing the initial concentration and time of water addition.
- a method for producing 2- (3-cyan-4-isobutyloxyphenyl) 4-methyl-5-thiazolecarboxylic acid, crystals A, G, or a mixture of crystals A and G is disclosed.
- Patent document 1 International publication W099Z65885 specification
- Patent Document 2 Japanese Patent Laid-Open No. 2003-261548
- An object of the present invention is to selectively obtain crystal A of 2- (3-cyan-4-isobutyloxyphenyl) 4-methyl-5-thiazolecarboxylic acid under conditions suitable for industrialization.
- Such a challenge is 2- (3-cyan-4-isobutyloxyphenyl) -4-methyl-5- Thiazolecarboxylic acid in methanol or methanol z water mixed solvent (however, methanol
- the amount of seeding and amount of seeding should be set in the condition indicated by area I in Fig. 2, or these two conditions are proportional to the rate of water addition. This is solved by a method characterized in that the condition is equivalent to the region I obtained by insertion.
- the condition corresponding to the region I obtained by interpolating these two conditions in proportion to the water addition rate will be described.
- the coordinates of the lower right vertex of the rectangular area shown as region I in Fig. 1 is (1.25 mg / mL, 40 minutes)
- the corresponding vertex in Fig. 2 is (1.25 mg / mL, 25 minutes). It is.
- the coordinates of the corresponding vertex in the water addition rate 0. OlOmLZ min Zm L are obtained.
- the horizontal axis is 1.25 mgZmL
- the vertical axis is ⁇ , 40 minutes + (25 minutes to 40 minutes) X (0.
- the above purposes force s achieved by a range of forces present invention are those with interpolation based on the value of the water addition rate, r ⁇ 0. 007, r> 0. 01175 ( units of mL / min / mL ) May be extrapolated.
- other specific conditions can be easily calculated based on the pre-determined pre-determined water addition rate. If so, it can be easily determined by trial.
- the present invention has found that by allowing a specific amount of seed crystals to act at a specific time, crystal A can be obtained even in a conventional solvent composition that is not considered to be obtained. Is.
- 2- (3-cyano 4-isobutyloxyphenyl) 4-methyl 5 thiazoyl carboxylic acid crystal A is represented by a reflection angle 2 ⁇ of approximately 6.62 °, 7 18 °, 12.80 °, 13.26 °, 16.48 °, 19.58 °, 21.92 °, 22.68 °, 25.84 °, 26.70 °, 29.16 °, and 36.
- the infrared spectroscopy can also be expressed as polymorph having characteristic absorption distinguishable from other crystalline polymorphs near 1678cm _1. See the specification of international publication W099Z65885.
- the effect of the present invention is that a solvate or a mixture of a solvate and a hydrate can be obtained without seed crystals, and crystal A can be selectively obtained by adding seed crystals. More specifically, according to this method, there is an advantage that crystals A can be selectively obtained even under conditions of 40 ° C. or lower where only methanol hydrates or hydrates are precipitated by the conventional technique. That is, according to the present invention, the crystal A of 2- (3-cyan-4-isobutyloxyphenyl) 4-methyl 5-thiazoylcarboxylic acid is reduced while reducing the possibility of mixing other crystal forms. It can be manufactured under conditions suitable for.
- FIG. 1 is an example of a condition diagram of seed crystal addition amount, seed crystal addition time, and water addition rate in the production method of the present invention.
- FIG. 2 is an example of a condition diagram of seed crystal addition amount, seed crystal addition timing, and water addition rate in the production method of the present invention.
- the composition ratio of methanol-water at the time of dissolution is 90Z10 (capacity (L) ratio, the same applies hereinafter) for methanol Z water.
- the range from 97Z3 to 95Z5, particularly 95Z5 is preferable.
- the initial concentration of the solute is preferably in the range of 0.024 ⁇ 0.008 molZL.
- it is preferably in the range of 0.024 ⁇ 0.004 molZL, particularly preferably 0.024 molZL.
- the amount of seed crystal added per initial solution amount is preferably 20 mg Z 40 mL or more.
- the preferable water addition rate is preferably in the range of 0.25-0.50 mLZ for 40 mL of the pre-addition solution.
- a suitable seed crystal addition amount and water addition rate are determined in proportion to the initial solution amount based on the above values.
- Crystalline A of 2- (3 cyano-4-isoptyloxyphenyl) -4-methyl-5-thiazolecarboxylic acid obtained by the production method of the present invention is used as a pharmaceutical product.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008522538A JP5193863B2 (ja) | 2006-06-23 | 2007-06-22 | 2−(3−シアノ−4−イソブチルオキシフェニル)−4−メチル−5−チアゾールカルボン酸の結晶多形体の製造方法 |
US12/306,170 US8148542B2 (en) | 2006-06-23 | 2007-06-22 | Method for producing crystal polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid |
CA2656264A CA2656264C (en) | 2006-06-23 | 2007-06-22 | Method for producing crystal polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid |
EP07767403.4A EP2039691B1 (en) | 2006-06-23 | 2007-06-22 | Process for production of a polymorph of 2-(3-cyano-4- isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006173774 | 2006-06-23 | ||
JP2006-173774 | 2006-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007148787A1 true WO2007148787A1 (ja) | 2007-12-27 |
Family
ID=38833524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/062593 WO2007148787A1 (ja) | 2006-06-23 | 2007-06-22 | 2-(3-シアノ-4-イソブチルオキシフェニル)-4-メチル-5-チアゾールカルボン酸の結晶多形体の製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8148542B2 (ja) |
EP (1) | EP2039691B1 (ja) |
JP (1) | JP5193863B2 (ja) |
CA (1) | CA2656264C (ja) |
WO (1) | WO2007148787A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010083752A1 (zh) * | 2009-01-20 | 2010-07-29 | 重庆医药工业研究院有限责任公司 | 一种高纯度的非布司他及其制备方法 |
WO2015174411A1 (ja) * | 2014-05-13 | 2015-11-19 | 帝人ファーマ株式会社 | ピリジン誘導体の新規な結晶多形体およびその製造方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2532654A1 (en) * | 2009-06-10 | 2012-12-12 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of febuxostat |
WO2011080651A2 (en) | 2009-12-31 | 2011-07-07 | Ranbaxy Laboratories Limited | Polymorphic forms of febuxostat |
AU2011222462A1 (en) | 2010-03-04 | 2012-09-27 | Ranbaxy Laboratories Limited | Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid |
WO2012098501A1 (en) * | 2011-01-21 | 2012-07-26 | Ranbaxy Laboratories Limited | Febuxostat co-crystals |
EP2502920A1 (en) | 2011-03-25 | 2012-09-26 | Sandoz Ag | Crystallization process of Febuxostat from A |
US20150031732A1 (en) | 2011-04-15 | 2015-01-29 | Ranbaxy Laboratories Limited | Febuxostat solid dispersion |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999065885A1 (en) | 1998-06-19 | 1999-12-23 | Teijin Limited | Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof |
JP2003261548A (ja) | 2002-03-07 | 2003-09-19 | Teijin Ltd | 2−(3−シアノ−4−イソブチルオキシフェニル)−4−メチル−5−チアゾールカルボン酸の結晶多形体の製造方法 |
-
2007
- 2007-06-22 JP JP2008522538A patent/JP5193863B2/ja active Active
- 2007-06-22 US US12/306,170 patent/US8148542B2/en active Active
- 2007-06-22 EP EP07767403.4A patent/EP2039691B1/en active Active
- 2007-06-22 CA CA2656264A patent/CA2656264C/en active Active
- 2007-06-22 WO PCT/JP2007/062593 patent/WO2007148787A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999065885A1 (en) | 1998-06-19 | 1999-12-23 | Teijin Limited | Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof |
JP2003261548A (ja) | 2002-03-07 | 2003-09-19 | Teijin Ltd | 2−(3−シアノ−4−イソブチルオキシフェニル)−4−メチル−5−チアゾールカルボン酸の結晶多形体の製造方法 |
Non-Patent Citations (4)
Title |
---|
KITAMURA M. ET AL.: "Effect of Temperature on Antisolvent Crystallization and Transformation Behaviors of Thiazole-Derivative Polymorphs", CRYSTAL GROWTH & DESIGN, vol. 6, no. 5, 2006, pages 1214 - 1218, XP003020202 * |
KITAMURA M.: "Controlling Factors and Mechanism of Polymorphism Crystallization", CRYSTAL GROWTH & DESIGN, vol. 4, no. 6, 2004, pages 1153 - 1159, XP003020203 * |
KITAMURA; HANADA; NAKAMURA: "International Symposium on Industrial Crystallization", CRYSTALLIZATION AND TRANSFORMATION BEHAVIOR OF THIAZOLE-DERIVATIVE, 21 September 1998 (1998-09-21) |
See also references of EP2039691A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010083752A1 (zh) * | 2009-01-20 | 2010-07-29 | 重庆医药工业研究院有限责任公司 | 一种高纯度的非布司他及其制备方法 |
WO2015174411A1 (ja) * | 2014-05-13 | 2015-11-19 | 帝人ファーマ株式会社 | ピリジン誘導体の新規な結晶多形体およびその製造方法 |
JPWO2015174411A1 (ja) * | 2014-05-13 | 2017-04-20 | 帝人ファーマ株式会社 | ピリジン誘導体の新規な結晶多形体およびその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2656264C (en) | 2014-07-08 |
US20090203919A1 (en) | 2009-08-13 |
EP2039691B1 (en) | 2013-09-18 |
US8148542B2 (en) | 2012-04-03 |
EP2039691A4 (en) | 2010-11-24 |
JP5193863B2 (ja) | 2013-05-08 |
CA2656264A1 (en) | 2007-12-27 |
JPWO2007148787A1 (ja) | 2009-11-19 |
EP2039691A1 (en) | 2009-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007148787A1 (ja) | 2-(3-シアノ-4-イソブチルオキシフェニル)-4-メチル-5-チアゾールカルボン酸の結晶多形体の製造方法 | |
JP7145931B2 (ja) | 化合物の結晶多形、その製造方法及び用途 | |
JP5519201B2 (ja) | 2−(3−シアノ−4−イソブチルオキシフェニル)−4−メチル−5−チアゾールカルボン酸の結晶多形体の製造方法 | |
JP5654462B2 (ja) | 貧溶媒添加法による2−(3−シアノ−4−イソブチルオキシフェニル)−4−メチル−5−チアゾールカルボン酸の結晶多形体の製造方法 | |
CN105377840B (zh) | 一种二氮杂环庚烷化合物的盐及其晶型与无定型物 | |
TW201313703A (zh) | 阿齊沙坦的新晶型及其製備方法 | |
US20090076272A1 (en) | Polymorphs of eszopiclone malate | |
WO2016107289A1 (zh) | 制备索非布韦晶型6的方法 | |
CN104829673A (zh) | 一种索氟布韦晶型6的制备方法 | |
JP2003261548A (ja) | 2−(3−シアノ−4−イソブチルオキシフェニル)−4−メチル−5−チアゾールカルボン酸の結晶多形体の製造方法 | |
JP4015954B2 (ja) | トシル酸スプラタスト結晶 | |
WO2001032608A1 (fr) | Procédé de préparation de dérivés d'acide oxyminoalcanoïque | |
WO2020053660A1 (en) | Solid forms of a bet inhibitor | |
CN107602525A (zh) | 一种盐酸哌泊索仑成盐及其结晶方法 | |
KR100917593B1 (ko) | 덱시부프로펜염의 제조방법 | |
CN108218872A (zh) | 一种艾代拉利司晶型c及其制备方法 | |
WO2002060441A1 (en) | Novel forms of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo (1,2-a)pyridine-6-carboxamide | |
Fini et al. | Effect of the temperature on a hydrate diclofenac salt | |
EP3115360A1 (en) | Crystal form of dabigatran etexilate mesylate and preparation method and use thereof | |
CN107868117B (zh) | 司坦唑醇糖精盐及其制备方法和应用 | |
KR101129575B1 (ko) | 반수화물 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법 | |
CN116396219A (zh) | 一种卡马西平-橙皮素球形共晶及其结晶制备方法 | |
Tandon et al. | Effect of seeding on sucrose polymorphism | |
JP2021520363A (ja) | 結晶形態のピモジビル塩酸塩半水和物を調製するための等温反応性結晶化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07767403 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008522538 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2656264 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12306170 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007767403 Country of ref document: EP |